Date: 2013-09-18
Type of information: Treatment of the first patient
phase: 2b
Announcement: treatment of the first patients
Company: Creabilis (Luxembourg)
Product: CT327 (TrkA kinase inhibitor )
Action
mechanism: CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis’ LSE (Low Systemic Exposure) technology. LSE technology creates new chemical entities which allow high local concentrations combined with low systemic exposure. CT327 acts to inhibit neurogenic inflammation and targets sensory neurones implicated in the pathology of chronic pruritus.
Disease: atopic dermatitis
pruritus
Therapeutic area: Dermatological diseases - Immunological diseases - Inflammatory diseases
Country:
Trial
details: The Phase 2b trial is a multi-centre, randomised, double-blind, placebo-controlled study in adult and adolescent patients (older than 12 years) with mild to moderate atopic dermatitis and at least moderate pruritus. The primary endpoints will assess pruritus using a visual analogue scale (VAS), and control of disease determined by Investigator Global Assessment (IGA). Quality of life measures will also be analysed. Two hundred and ten patients are expected to be enrolled and results are anticipated in Q2 of 2014.
Latest
news: * On September 18, 2013, Creabilis, a late clinical stage European dermatology company with a focus on pruritus, has announced it has treated the first patients in its Phase 2b study of its lead product, CT327, in patients with atopic dermatitis. Two hundred and ten patients are expected to be enrolled and results are anticipated in Q2 of 2014. Creabilis has already demonstrated a statistically significant and clinically meaningful reduction of pruritus and an improvement in psoriasis symptoms when compared to placebo vehicle in psoriasis patients treated with CT327 in a previous Phase 2b trial.
Last November, Creabilis has been granted a Biomedical Catalyst funding award of £1.42m. This award is used to partly support this study.
